Table 7.
Expression of STS and SULTs in ovarian cancer.
| Gene | Level | Regulation | References |
|---|---|---|---|
| STS | mRNA | ≈ EOC/OSE | Ren et al., 2015 |
| Protein | Expressed EOC and OSE | Ren et al., 2015 | |
| 70% OCCA; 33% serous and 50% mucinous adenocarcinoma | Okuda et al., 2001 | ||
| 17% Cancer low/moderate Normal ovary low (stromal cells) | Human Protein Atlas | ||
| Activity (E1-S) |
 SKOV-3, PEO-1 vs. OSE |
Ren et al., 2015 | |
STS  progression-free survival |
Chura et al., 2009 | ||
| SULT1E1 | mRNA |
EOC/OSE |
Ren et al., 2015 |
| Protein | Expressed EOC and OSE | Ren et al., 2015 | |
| 17% Cancer moderate/normal ND | Human Protein Atlas | ||
| Activity (E1) |
SKOV-3, PEO-1 vs. OSE |
Ren et al., 2015 | |
| SULT2A1 | Protein | 17%-50% Cancer low/moderate Normal ovary/ND | Human Protein Atlas |
| SULT2B1 | Protein | 58%-100% Cancer moderate Normal ovary/weak | Human Protein Atlas |
EOC, epithelial ovarian carcinoma; OSE, ovarian surface epithelia; OCCA, ovarian clear-cell adenocarcinoma.